IL1B and cancer: Reports from the literature suggest the significant inhibition of IL-1β in response to pyrazinib (P3) is a positive effect which may contribute to the anti-cancer activity of this drug in addition to its effects on oxidative phosphorylation in vitro and ex vivo and radiosensitivity in vitro.